In human colonic cancer cells (HT29-18N2), TRPM5 channels have the potential as pharmacological targets for managing mucus-associated pathologies, such as cystic fibrosis [46], given their roles in regulating Ca2+-mediated mucin 2 and MUC5AC secretion [47]. This evidence concerns the gene MUC5AC and malignant colon neoplasm.